User login
In 2012 legislation known as the FDA Safety and Innovation Act, the Food and Drug Administration was authorized to conduct a series of 20 public meetings focusing on specific diseases to enhance understanding of the patient experience. Now, the FDA has announced that patient organizations whose diseases were not included in this series may organize their own meetings for this purpose. Learn more about this in an FDA blog and on the FDA website.
In 2012 legislation known as the FDA Safety and Innovation Act, the Food and Drug Administration was authorized to conduct a series of 20 public meetings focusing on specific diseases to enhance understanding of the patient experience. Now, the FDA has announced that patient organizations whose diseases were not included in this series may organize their own meetings for this purpose. Learn more about this in an FDA blog and on the FDA website.
In 2012 legislation known as the FDA Safety and Innovation Act, the Food and Drug Administration was authorized to conduct a series of 20 public meetings focusing on specific diseases to enhance understanding of the patient experience. Now, the FDA has announced that patient organizations whose diseases were not included in this series may organize their own meetings for this purpose. Learn more about this in an FDA blog and on the FDA website.